Kronos Bio (KRON) Competitors $0.88 +0.02 (+2.56%) As of 11:15 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRON vs. IMMP, CRVS, YMAB, FHTX, PROK, CADL, CRGX, DSGN, ENGN, and PLXShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Immutep (IMMP), Corvus Pharmaceuticals (CRVS), Y-mAbs Therapeutics (YMAB), Foghorn Therapeutics (FHTX), ProKidney (PROK), Candel Therapeutics (CADL), CARGO Therapeutics (CRGX), Design Therapeutics (DSGN), enGene (ENGN), and Protalix BioTherapeutics (PLX). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. Immutep Corvus Pharmaceuticals Y-mAbs Therapeutics Foghorn Therapeutics ProKidney Candel Therapeutics CARGO Therapeutics Design Therapeutics enGene Protalix BioTherapeutics Immutep (NASDAQ:IMMP) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings, valuation and community ranking. Which has stronger valuation and earnings, IMMP or KRON? Immutep has higher earnings, but lower revenue than Kronos Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmutep$5.14M47.73-$28.01MN/AN/AKronos Bio$9.85M5.33-$112.67M-$1.43-0.60 Which has more volatility and risk, IMMP or KRON? Immutep has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Kronos Bio has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Is IMMP or KRON more profitable? Immutep has a net margin of 0.00% compared to Kronos Bio's net margin of -867.66%. Immutep's return on equity of 0.00% beat Kronos Bio's return on equity.Company Net Margins Return on Equity Return on Assets ImmutepN/A N/A N/A Kronos Bio -867.66%-64.55%-48.18% Do analysts rate IMMP or KRON? Immutep currently has a consensus price target of $8.50, indicating a potential upside of 405.95%. Kronos Bio has a consensus price target of $1.63, indicating a potential upside of 88.73%. Given Immutep's stronger consensus rating and higher possible upside, research analysts clearly believe Immutep is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immutep 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor IMMP or KRON? In the previous week, Kronos Bio had 2 more articles in the media than Immutep. MarketBeat recorded 2 mentions for Kronos Bio and 0 mentions for Immutep. Kronos Bio's average media sentiment score of 1.43 beat Immutep's score of 0.00 indicating that Kronos Bio is being referred to more favorably in the news media. Company Overall Sentiment Immutep Neutral Kronos Bio Positive Do insiders & institutionals believe in IMMP or KRON? 2.3% of Immutep shares are owned by institutional investors. Comparatively, 64.1% of Kronos Bio shares are owned by institutional investors. 3.1% of Immutep shares are owned by company insiders. Comparatively, 24.4% of Kronos Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor IMMP or KRON? Immutep received 291 more outperform votes than Kronos Bio when rated by MarketBeat users. Likewise, 72.56% of users gave Immutep an outperform vote while only 65.63% of users gave Kronos Bio an outperform vote. CompanyUnderperformOutperformImmutepOutperform Votes31272.56% Underperform Votes11827.44% Kronos BioOutperform Votes2165.63% Underperform Votes1134.38% SummaryImmutep beats Kronos Bio on 11 of the 16 factors compared between the two stocks. Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.66M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.607.0522.2418.31Price / Sales5.33273.45397.24107.04Price / CashN/A65.6738.2034.62Price / Book0.326.506.844.25Net Income-$112.67M$142.50M$3.20B$247.51M7 Day Performance-3.04%8.32%5.79%6.86%1 Month Performance0.96%-5.61%-4.29%-2.95%1 Year Performance-12.14%0.11%17.99%5.17% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio3.5917 of 5 stars$0.88+2.6%$1.63+84.0%-10.3%$53.84M$9.85M-0.62100Positive NewsIMMPImmutep1.0473 of 5 stars$1.51-1.9%$8.50+462.9%-35.1%$220.52M$5.14M0.002,021News CoveragePositive NewsCRVSCorvus Pharmaceuticals2.8313 of 5 stars$3.22-0.6%$15.67+386.5%+142.4%$219.40MN/A-3.4630High Trading VolumeYMABY-mAbs Therapeutics3.6088 of 5 stars$4.82+2.8%$18.30+279.7%-73.0%$217.95M$87.69M-8.93150Analyst DowngradeAnalyst RevisionNews CoveragePositive NewsFHTXFoghorn Therapeutics3.0597 of 5 stars$3.90+2.6%$13.17+237.6%-14.2%$216.89M$22.60M-2.03120Analyst ForecastNews CoveragePROKProKidney2.3705 of 5 stars$0.73-7.3%$5.00+582.2%-63.5%$214.52M$76,000.00-1.333Insider TradePositive NewsCADLCandel Therapeutics2.1554 of 5 stars$4.51-1.3%$21.00+365.6%-17.4%$213.03M$120,000.00-2.6160Gap UpCRGXCARGO Therapeutics2.9708 of 5 stars$4.60-0.9%$15.00+226.1%-75.8%$211.84MN/A-1.08116Positive NewsHigh Trading VolumeDSGNDesign Therapeutics1.6499 of 5 stars$3.59+2.6%$8.00+122.8%+16.2%$203.78MN/A-4.2240News CoveragePositive NewsENGNenGene3.1727 of 5 stars$3.99-0.3%$24.13+504.6%-72.9%$203.40MN/A-6.8831PLXProtalix BioTherapeutics1.9633 of 5 stars$2.55-2.3%$15.00+488.2%+140.9%$198.98M$53.40M-19.62200 Related Companies and Tools Related Companies IMMP Competitors CRVS Competitors YMAB Competitors FHTX Competitors PROK Competitors CADL Competitors CRGX Competitors DSGN Competitors ENGN Competitors PLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRON) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRON Stock Free KRON Stock Alerts